Welcome to our dedicated page for AMAG news (Ticker: AMAG), a resource for investors and traders seeking the latest updates and insights on AMAG stock.
AMAG Pharmaceuticals, Inc. (AMAG) is a biopharmaceutical innovator focused on therapeutic iron treatments and women's health solutions. This page provides centralized access to official announcements, financial updates, and strategic developments impacting the company's trajectory in healthcare innovation.
Investors and industry professionals will find timely updates on AMAG's product portfolio, including Feraheme for iron deficiency anemia and collaborations advancing medical safety technologies. The resource aggregates earnings reports, regulatory milestones, and partnership announcements to support data-driven decision-making.
Key content categories include treatment approvals, acquisition developments (such as the Perosphere Pharmaceuticals integration), leadership changes affecting corporate strategy, and research advancements across AMAG's therapeutic areas. All materials maintain compliance with financial disclosure standards.
Bookmark this page for streamlined monitoring of AMAG's progress in addressing critical health needs through biopharmaceutical innovation. Regular updates ensure stakeholders remain informed about developments directly influencing the company's market position and therapeutic impact.
AMAG Pharmaceuticals has mutually terminated its license agreement with Palatin Technologies regarding the development and commercialization of Vyleesi® (bremelanotide) for hypoactive sexual desire disorder in premenopausal women. AMAG will pay Palatin $16.3 million for the return of Vyleesi, allowing AMAG to reduce operating expenses and focus on other key assets like ciraparantag and Feraheme. This strategic shift aims to enhance the company's future value while maintaining patient access to Vyleesi during the transition.
AMAG Pharmaceuticals has entered an exclusive licensing agreement with Norgine for the development and commercialization of ciraparantag across Europe, Australia, and New Zealand. The deal includes a $30 million upfront payment and eligibility for up to $260 million in development and commercial milestones, alongside escalating royalties. The partnership focuses on ciraparantag's use as a reversal agent for anticoagulants in emergency situations. AMAG will oversee the Phase 3 clinical program, while Norgine will handle regulatory filings in its territories.
AMAG Pharmaceuticals announced data from two Phase 2 studies at the ISTH virtual annual meeting, showcasing the safety and efficacy of ciraparantag in reversing apixaban and rivaroxaban effects in healthy adults aged 50-75. Results indicated that a single IV infusion of ciraparantag reversed anticoagulation effectively and safely, achieving targeted WBCT levels within one hour for 100% of subjects receiving sufficient doses. Ciraparantag was well tolerated with mild adverse events noted. This data supports further studies on ciraparantag for patients needing rapid anticoagulation reversal.
AMAG Pharmaceuticals has announced the departure of Chief Financial and Chief Operating Officer, Edward Myles. In his place, Brian Piekos has been named interim CFO, with extensive experience in finance including strategic planning and capital market activities. Anthony Casciano has been promoted to COO, adding more operational responsibilities. Both appointments are effective immediately and aim to strengthen AMAG’s leadership to enhance business growth, advance its product pipeline, and unlock shareholder value.
AMAG Pharmaceuticals has successfully sold its rights to Intrarosa to Millicent Pharma for a total of up to $125 million, which includes a $20 million upfront payment and potential milestone payments based on sales. This strategic move aligns with AMAG's focus on its key products, Feraheme and Makena, while divesting women's health assets. The sale is seen as a pivotal step in their evolution, with AMAG also planning to divest Vyleesi. Millicent Pharma's expertise is expected to enhance Intrarosa's market growth.
